About Us Strategy & Mission Our Values Our People Our Board Our Scientific Advisors Our Collaborations Contact Our Programs Pipeline C. difficile Infection Enterobacteriaceae Clinical Trials Innovation Engine New Era Microbiome Therapeutics Discuva Platform Scientific Literature & Publications Investors & Media Investor Center Media Center Press Releases Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Summit Presentations Careers
Analysis of C. difficile Isolated from Stools of Patients Enrolled in a Phase II Clinical Trial of Ridinilazole (SMT 19969) Analysis of C. difficile Isolated from Stools of Patients Enrolled in a Phase II Clinical Trial of Ridinilazole (SMT 19969) June 20, 2016 By CKD Digital
Analysis of C. difficile Isolated from Stools of Patients Enrolled in a Phase II Clinical Trial of Ridinilazole (SMT 19969)
Analysis of C. difficile Isolated from Stools of Patients Enrolled in a Phase II Clinical Trial of Ridinilazole (SMT 19969) June 20, 2016 By CKD Digital